Colestipol BE study design [Design Issues]

posted by cakhatri – India, 2014-02-27 16:23 (3704 d 09:48 ago) – Posting: # 12527
Views: 5,606

Dear Members,

We have a requirement for conduct of BE study on Colestipol tablets for USFDA submission. There is no BE recommendation from FDA and no reference literature is available through which the design can be concluded. Upon review of the literature, the indication seems to be similar to Cholestyramine, for which FDA has guideline for conduct of in-vitro equilibrium binding study and in-vitro kinetic study

Can the same be applied to Colestipol, or can anyone share their experience with Colestipol

Best Regards
Chirag

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,656 registered users;
92 visitors (0 registered, 92 guests [including 4 identified bots]).
Forum time: 03:11 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5